This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Pernix Therapeutics Holdings Reports Second Quarter 2011 Financial Results

Pernix Therapeutics Holdings, Inc. (“Pernix”) (NYSE Amex: PTX), a specialty pharmaceutical company primarily focused on the pediatric market, today announced financial results for the second quarter and first half of 2011.

Financial Results

For the second quarter of 2011, net revenues increased by approximately 178% to $12.0 million, compared to $4.3 million for the second quarter of 2010. The increase in net revenues was due primarily to higher volume of sales including the Company’s new CEDAX product formulation and certain generic products.

Net income for the second quarter of 2011 was approximately $1.5 million, or $0.07 per basic and diluted share, as compared to $0.2 million, or $0.01 per basic and diluted share, for the second quarter of 2010. Selling, general and administrative (“SG&A”) expenses in the second quarter of 2011 increased to approximately $4.7 million, as compared to approximately $2.8 million for the second quarter of 2010, primarily due to the doubling of the Company’s sales force and the addition of several key management positions in 2010. Depreciation and amortization expense increased to approximately $0.6 million for the second quarter of 2011, as compared to approximately $0.2 million for the second quarter of 2010. The increase is due to the amortization under certain commercial agreements, including the Company’s acquisitions of CEDAX and Macoven in 2010. The Company also recognized approximately $0.3 million in expenses related to its joint venture with SEEK for the development of Theobromine during the second quarter of 2011. For the second quarter of 2011, the Company recognized an income tax expense of approximately $0.9 million, as compared to an income tax expense of approximately $0.2 million for the second quarter of 2010.

Earnings before interest, taxes, depreciation and amortization (EBITDA, a non-GAAP measure) increased by approximately 435% to approximately $3.0 million for the second quarter of 2011, compared to approximately $0.6 million for the second quarter of 2010. See the table at the end of this press release for a reconciliation of EBITDA to GAAP net income.

1 of 7

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 17,826.30 -279.47 -1.54%
S&P 500 2,081.18 -23.81 -1.13%
NASDAQ 4,931.8150 -75.9760 -1.52%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs